Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Stopped early

Conditions studied: Breast Cancer

In brief

RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.

Key facts

Study ID

NCT00899197

Run by

Wake Forest University Health Sciences

People needed

2

Starts

2007-05-01

Expected to finish

2012-06-01

Last updated by the study team

2017-08-01

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed invasive breast cancer
• Initial pathologic stage I-IIIB disease
• No stage IV disease
• Meets the following criteria for breast cancer therapy:
• Received prior primary local therapy for breast cancer
• Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks
• Hormone receptor status:
• Estrogen-receptor positive tumor
• Female
• Pre- or post-menopausal
• Must be able to donate 20 mL of blood

You may not qualify if…

• Severe anemia, defined as hemoglobin < 11 g/dL
• Psychiatric history that would preclude obtaining informed consent

Where it is running

• Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.